Skip to main content
Erschienen in: Familial Cancer 2/2013

01.06.2013 | Original Article

The History of Lynch Syndrome

verfasst von: C. Richard Boland, Henry T. Lynch

Erschienen in: Familial Cancer | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Excerpt

One hundred years ago, Aldred Scott Warthin, MD, PhD, [1] Chairman of the Department of Pathology at the University of Michigan in Ann Arbor, reported the first family with the disease we now call Lynch Syndrome (Fig. 1). In 1895, a woman who worked as his seamstress reported distress over the fact that many family members over several generations had succumbed to cancer, and she feared the same for herself. Indeed, she developed endometrial cancer, and died of that disease as she predicted. Warthin dryly noted that “the statistical study of carcinoma … [has] been carried as far as it can be profitable; and certainly but little that is new has been gained by this method during the last decade”. Throwing a statistical approach to the wind, he undertook a “fairly complete survey” of the family, and created a pedigree, showing which family members had developed cancer, and their relationships (Fig. 2).
Literatur
1.
Zurück zum Zitat Warthin AS (1913) Heredity with reference to carcinoma as shown by the study of the cases examined in the Pathological Laboratory of the University of Michigan, 1895–1912. Arch Int Med 12:546–555CrossRef Warthin AS (1913) Heredity with reference to carcinoma as shown by the study of the cases examined in the Pathological Laboratory of the University of Michigan, 1895–1912. Arch Int Med 12:546–555CrossRef
2.
Zurück zum Zitat Warthin AS (1925) The further study of a cancer family. J Cancer Res 9:279–286 Warthin AS (1925) The further study of a cancer family. J Cancer Res 9:279–286
3.
Zurück zum Zitat Hauser IJ, Weller CV (1936) A further report on the cancer family of Warthin. Am J Cancer 27:434–449CrossRef Hauser IJ, Weller CV (1936) A further report on the cancer family of Warthin. Am J Cancer 27:434–449CrossRef
4.
Zurück zum Zitat Bargen JA, Mayo CW, Giffin LA (1941) Familial trends in human cancer. J Heredity 32:7 Bargen JA, Mayo CW, Giffin LA (1941) Familial trends in human cancer. J Heredity 32:7
5.
Zurück zum Zitat Savage D (1956) A family history of uterine and gastro-intestinal cancer. Br Med J 2(4988):341–343PubMedCrossRef Savage D (1956) A family history of uterine and gastro-intestinal cancer. Br Med J 2(4988):341–343PubMedCrossRef
6.
Zurück zum Zitat Aure JC, Nilsson S (1964) Familial disposition of cancer of the gastrointestinal tract. Acta Chir Scand 129:644–648 Aure JC, Nilsson S (1964) Familial disposition of cancer of the gastrointestinal tract. Acta Chir Scand 129:644–648
7.
Zurück zum Zitat Bieler VV, Heim U (1965) Double cancer in siblings. Familial association of cancer of the genitaliia and intestines. Schweiz Med Wochenschr 95:496–497PubMed Bieler VV, Heim U (1965) Double cancer in siblings. Familial association of cancer of the genitaliia and intestines. Schweiz Med Wochenschr 95:496–497PubMed
8.
Zurück zum Zitat Glidzic V, Petrovic G (1968) Hereditary nature of cancers of the colon. Bull Cancer 55(4):511–516PubMed Glidzic V, Petrovic G (1968) Hereditary nature of cancers of the colon. Bull Cancer 55(4):511–516PubMed
9.
Zurück zum Zitat Kartagener M, Wyler J (1966) Familial incidence of double malignancies. Schweiz Med Wochenschr 96(7):218–219PubMed Kartagener M, Wyler J (1966) Familial incidence of double malignancies. Schweiz Med Wochenschr 96(7):218–219PubMed
10.
Zurück zum Zitat Kluge T (1964) Familial cancer of the colon. Acta Chir Scand 127:392–398PubMed Kluge T (1964) Familial cancer of the colon. Acta Chir Scand 127:392–398PubMed
11.
Zurück zum Zitat Heinzelmann F (1964) On a cancer family. A contribution to the problem of the hereditary aspects of colonic carcinoma. Helv Chir Acta 31:316–324PubMed Heinzelmann F (1964) On a cancer family. A contribution to the problem of the hereditary aspects of colonic carcinoma. Helv Chir Acta 31:316–324PubMed
12.
Zurück zum Zitat Lynch HT, Shaw MW, Magnuson CW, Larsen AL, Krush AJ (1966) Hereditary factors in cancer. Study of two large midwestern kindreds. Arch Intern Med 117(2):206–212PubMedCrossRef Lynch HT, Shaw MW, Magnuson CW, Larsen AL, Krush AJ (1966) Hereditary factors in cancer. Study of two large midwestern kindreds. Arch Intern Med 117(2):206–212PubMedCrossRef
13.
Zurück zum Zitat Lynch HT, Krush AJ (1967) Heredity and adenocarcinoma of the colon. Gastroenterology 53(4):517–527PubMed Lynch HT, Krush AJ (1967) Heredity and adenocarcinoma of the colon. Gastroenterology 53(4):517–527PubMed
14.
Zurück zum Zitat Lynch HT, Krush AJ, Larsen AL (1967) Heredity and multiple primary malignant neoplasms: six cancer families. Am J Med Sci 254(3):322–329PubMedCrossRef Lynch HT, Krush AJ, Larsen AL (1967) Heredity and multiple primary malignant neoplasms: six cancer families. Am J Med Sci 254(3):322–329PubMedCrossRef
15.
Zurück zum Zitat Lynch HT, Krush AJ (1971) Cancer family “G” revisited: 1895–1970. Cancer 27(6):1505–1511PubMedCrossRef Lynch HT, Krush AJ (1971) Cancer family “G” revisited: 1895–1970. Cancer 27(6):1505–1511PubMedCrossRef
16.
Zurück zum Zitat Douglas JA, Gruber SB, Meister KA et al (2005) History and molecular genetics of Lynch syndrome in family G: a century later. JAMA 294(17):2195–2202PubMedCrossRef Douglas JA, Gruber SB, Meister KA et al (2005) History and molecular genetics of Lynch syndrome in family G: a century later. JAMA 294(17):2195–2202PubMedCrossRef
17.
Zurück zum Zitat Boland CR (1978) Cancer family syndrome. A case report and literature review. Am J Dig Dis 23(5):25s–27sCrossRef Boland CR (1978) Cancer family syndrome. A case report and literature review. Am J Dig Dis 23(5):25s–27sCrossRef
18.
Zurück zum Zitat Boland CR, Troncale FJ (1984) Familial colonic cancer without antecedent polyposis. Ann Intern Med 100(5):700–701PubMedCrossRef Boland CR, Troncale FJ (1984) Familial colonic cancer without antecedent polyposis. Ann Intern Med 100(5):700–701PubMedCrossRef
19.
Zurück zum Zitat Lynch HT, Riegert-Johnson DL, Snyder C et al (2011) Lynch syndrome-associated extracolonic tumors are rare in two extended families with the same EPCAM deletion. Am J Gastroenterol 106(10):1829–1836PubMedCrossRef Lynch HT, Riegert-Johnson DL, Snyder C et al (2011) Lynch syndrome-associated extracolonic tumors are rare in two extended families with the same EPCAM deletion. Am J Gastroenterol 106(10):1829–1836PubMedCrossRef
20.
Zurück zum Zitat Lynch HT, Kimberling W, Albano WA et al (1985) Hereditary nonpolyposis colorectal cancer (Lynch syndromes I and II). I. Clinical description of resource. Cancer 56(4):934–938PubMedCrossRef Lynch HT, Kimberling W, Albano WA et al (1985) Hereditary nonpolyposis colorectal cancer (Lynch syndromes I and II). I. Clinical description of resource. Cancer 56(4):934–938PubMedCrossRef
21.
Zurück zum Zitat Lynch HT, Schuelke GS, Kimberling WJ et al (1985) Hereditary nonpolyposis colorectal cancer (Lynch syndromes I and II). II. Biomarker studies. Cancer 56(4):939–951PubMedCrossRef Lynch HT, Schuelke GS, Kimberling WJ et al (1985) Hereditary nonpolyposis colorectal cancer (Lynch syndromes I and II). II. Biomarker studies. Cancer 56(4):939–951PubMedCrossRef
22.
Zurück zum Zitat Boland CR (2005) Evolution of the nomenclature for the hereditary colorectal cancer syndromes. Fam Cancer 4(3):211–218PubMedCrossRef Boland CR (2005) Evolution of the nomenclature for the hereditary colorectal cancer syndromes. Fam Cancer 4(3):211–218PubMedCrossRef
23.
Zurück zum Zitat Lynch HT, Cristofaro G, Rozen P et al (2003) History of the international collaborative group on hereditary non polyposis colorectal cancer. Fam Cancer 2(suppl 1):3–5PubMedCrossRef Lynch HT, Cristofaro G, Rozen P et al (2003) History of the international collaborative group on hereditary non polyposis colorectal cancer. Fam Cancer 2(suppl 1):3–5PubMedCrossRef
24.
Zurück zum Zitat Vasen HF, Mecklin JP, Khan PM, Lynch HT (1991) The international collaborative group on hereditary non-polyposis colorectal cancer (ICG-HNPCC). Dis Colon Rectum 34(5):424–425PubMedCrossRef Vasen HF, Mecklin JP, Khan PM, Lynch HT (1991) The international collaborative group on hereditary non-polyposis colorectal cancer (ICG-HNPCC). Dis Colon Rectum 34(5):424–425PubMedCrossRef
25.
Zurück zum Zitat Vasen HF, Watson P, Mecklin JP, Lynch HT (1999) New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the international collaborative group on HNPCC. Gastroenterology 116(6):1453–1456PubMedCrossRef Vasen HF, Watson P, Mecklin JP, Lynch HT (1999) New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the international collaborative group on HNPCC. Gastroenterology 116(6):1453–1456PubMedCrossRef
26.
Zurück zum Zitat Marra G, Boland CR (1995) Hereditary nonpolyposis colorectal cancer: the syndrome, the genes, and historical perspectives. J Natl Cancer Inst 87(15):1114–1125PubMedCrossRef Marra G, Boland CR (1995) Hereditary nonpolyposis colorectal cancer: the syndrome, the genes, and historical perspectives. J Natl Cancer Inst 87(15):1114–1125PubMedCrossRef
27.
Zurück zum Zitat Neale K, Bulow S (2003) Origins of the leeds castle polyposis group. Fam Cancer 2(suppl 1):1–2PubMedCrossRef Neale K, Bulow S (2003) Origins of the leeds castle polyposis group. Fam Cancer 2(suppl 1):1–2PubMedCrossRef
28.
Zurück zum Zitat Peinado MA, Malkhosyan S, Velazquez A, Perucho M (1992) Isolation and characterization of allelic losses and gains in colorectal tumors by arbitrarily primed polymerase chain reaction. Proc Natl Acad Sci USA 89(21):10065–10069PubMedCrossRef Peinado MA, Malkhosyan S, Velazquez A, Perucho M (1992) Isolation and characterization of allelic losses and gains in colorectal tumors by arbitrarily primed polymerase chain reaction. Proc Natl Acad Sci USA 89(21):10065–10069PubMedCrossRef
29.
Zurück zum Zitat Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M (1993) Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 363(6429):558–561PubMedCrossRef Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M (1993) Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 363(6429):558–561PubMedCrossRef
30.
Zurück zum Zitat Thibodeau SN, Bren G, Schaid D (1993) Microsatellite instability in cancer of the proximal colon. Science 260(5109):816–819PubMedCrossRef Thibodeau SN, Bren G, Schaid D (1993) Microsatellite instability in cancer of the proximal colon. Science 260(5109):816–819PubMedCrossRef
31.
Zurück zum Zitat Peltomaki P, Aaltonen LA, Sistonen P et al (1993) Genetic mapping of a locus predisposing to human colorectal cancer. Science 260(5109):810–812PubMedCrossRef Peltomaki P, Aaltonen LA, Sistonen P et al (1993) Genetic mapping of a locus predisposing to human colorectal cancer. Science 260(5109):810–812PubMedCrossRef
32.
Zurück zum Zitat Aaltonen LA, Peltomaki P, Leach FS et al (1993) Clues to the pathogenesis of familial colorectal cancer. Science 260(5109):812–816PubMedCrossRef Aaltonen LA, Peltomaki P, Leach FS et al (1993) Clues to the pathogenesis of familial colorectal cancer. Science 260(5109):812–816PubMedCrossRef
33.
Zurück zum Zitat Fishel R, Lescoe MK, Rao MR et al (1993) The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 75(5):1027–1038PubMedCrossRef Fishel R, Lescoe MK, Rao MR et al (1993) The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 75(5):1027–1038PubMedCrossRef
34.
Zurück zum Zitat Leach FS, Nicolaides NC, Papadopoulos N et al (1993) Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell 75(6):1215–1225PubMedCrossRef Leach FS, Nicolaides NC, Papadopoulos N et al (1993) Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell 75(6):1215–1225PubMedCrossRef
35.
Zurück zum Zitat Parsons R, Li GM, Longley MJ et al (1993) Hypermutability and mismatch repair deficiency in RER + tumor cells. Cell 75(6):1227–1236PubMedCrossRef Parsons R, Li GM, Longley MJ et al (1993) Hypermutability and mismatch repair deficiency in RER + tumor cells. Cell 75(6):1227–1236PubMedCrossRef
36.
Zurück zum Zitat Lindblom A, Tannergard P, Werelius B, Nordenskjold M (1993) Genetic mapping of a second locus predisposing to hereditary non-polyposis colon cancer. Nat Genet 5(3):279–282PubMedCrossRef Lindblom A, Tannergard P, Werelius B, Nordenskjold M (1993) Genetic mapping of a second locus predisposing to hereditary non-polyposis colon cancer. Nat Genet 5(3):279–282PubMedCrossRef
37.
Zurück zum Zitat Bronner CE, Baker SM, Morrison PT et al (1994) Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature 368(6468):258–261PubMedCrossRef Bronner CE, Baker SM, Morrison PT et al (1994) Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature 368(6468):258–261PubMedCrossRef
38.
Zurück zum Zitat Papadopoulos N, Nicolaides NC, Wei YF et al (1994) Mutation of a mutL homolog in hereditary colon cancer. Science 263(5153):1625–1629PubMedCrossRef Papadopoulos N, Nicolaides NC, Wei YF et al (1994) Mutation of a mutL homolog in hereditary colon cancer. Science 263(5153):1625–1629PubMedCrossRef
39.
Zurück zum Zitat Nicolaides NC, Papadopoulos N, Liu B et al (1994) Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. Nature 371(6492):75–80PubMedCrossRef Nicolaides NC, Papadopoulos N, Liu B et al (1994) Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. Nature 371(6492):75–80PubMedCrossRef
40.
Zurück zum Zitat Palombo F, Gallinari P, Iaccarino I et al (1995) GTBP, a 160-kilodalton protein essential for mismatch-binding activity in human cells. Science 268(5219):1912–1914PubMedCrossRef Palombo F, Gallinari P, Iaccarino I et al (1995) GTBP, a 160-kilodalton protein essential for mismatch-binding activity in human cells. Science 268(5219):1912–1914PubMedCrossRef
41.
Zurück zum Zitat Papadopoulos N, Nicolaides NC, Liu B et al (1995) Mutations of GTBP in genetically unstable cells. Science 268(5219):1915–1917PubMedCrossRef Papadopoulos N, Nicolaides NC, Liu B et al (1995) Mutations of GTBP in genetically unstable cells. Science 268(5219):1915–1917PubMedCrossRef
42.
Zurück zum Zitat Miyaki M, Konishi M, Tanaka K et al (1997) Germline mutation of MSH6 as the cause of hereditary nonpolyposis colorectal cancer. Nat Genet 17(3):271–272PubMedCrossRef Miyaki M, Konishi M, Tanaka K et al (1997) Germline mutation of MSH6 as the cause of hereditary nonpolyposis colorectal cancer. Nat Genet 17(3):271–272PubMedCrossRef
43.
Zurück zum Zitat Boland CR, Thibodeau SN, Hamilton SR et al (1998) A national cancer institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 58(22):5248–5257PubMed Boland CR, Thibodeau SN, Hamilton SR et al (1998) A national cancer institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 58(22):5248–5257PubMed
44.
Zurück zum Zitat Umar A, Boland CR, Terdiman JP et al (2004) Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 96(4):261–268PubMedCrossRef Umar A, Boland CR, Terdiman JP et al (2004) Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 96(4):261–268PubMedCrossRef
45.
Zurück zum Zitat Lindor NM, Rabe K, Petersen GM et al (2005) Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA 293(16):1979–1985PubMedCrossRef Lindor NM, Rabe K, Petersen GM et al (2005) Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA 293(16):1979–1985PubMedCrossRef
46.
Zurück zum Zitat Boland CR, Shike M (2010) Report from the Jerusalem workshop on Lynch syndrome-hereditary nonpolyposis colorectal cancer. Gastroenterology 138(7):2197PubMedCrossRef Boland CR, Shike M (2010) Report from the Jerusalem workshop on Lynch syndrome-hereditary nonpolyposis colorectal cancer. Gastroenterology 138(7):2197PubMedCrossRef
47.
Zurück zum Zitat Goel A, Xicola RM, Nguyen TP et al (2010) Aberrant DNA methylation in hereditary nonpolyposis colorectal cancer without mismatch repair deficiency. Gastroenterology 138(5):1854–1862PubMedCrossRef Goel A, Xicola RM, Nguyen TP et al (2010) Aberrant DNA methylation in hereditary nonpolyposis colorectal cancer without mismatch repair deficiency. Gastroenterology 138(5):1854–1862PubMedCrossRef
48.
Zurück zum Zitat Palomaki GE, McClain MR, Melillo S, Hampel HL, Thibodeau SN (2009) EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genet Med 11(1):42–65PubMedCrossRef Palomaki GE, McClain MR, Melillo S, Hampel HL, Thibodeau SN (2009) EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genet Med 11(1):42–65PubMedCrossRef
49.
Zurück zum Zitat Wijnen J, van der Klift H, Vasen H et al (1998) MSH2 genomic deletions are a frequent cause of HNPCC. Nat Genet 20(4):326–328PubMedCrossRef Wijnen J, van der Klift H, Vasen H et al (1998) MSH2 genomic deletions are a frequent cause of HNPCC. Nat Genet 20(4):326–328PubMedCrossRef
50.
Zurück zum Zitat Yan H, Papadopoulos N, Marra G et al (2000) Conversion of diploidy to haploidy. Nature 403(6771):723–724PubMedCrossRef Yan H, Papadopoulos N, Marra G et al (2000) Conversion of diploidy to haploidy. Nature 403(6771):723–724PubMedCrossRef
51.
Zurück zum Zitat Ligtenberg MJ, Kuiper RP, Chan TL et al (2009) Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3’ exons of TACSTD1. Nat Genet 41(1):112–117PubMedCrossRef Ligtenberg MJ, Kuiper RP, Chan TL et al (2009) Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3’ exons of TACSTD1. Nat Genet 41(1):112–117PubMedCrossRef
52.
Zurück zum Zitat Koi M, Umar A, Chauhan DP et al (1994) Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N’-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation. Cancer Res 54(16):4308–4312PubMed Koi M, Umar A, Chauhan DP et al (1994) Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N’-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation. Cancer Res 54(16):4308–4312PubMed
53.
Zurück zum Zitat Hawn MT, Umar A, Carethers JM et al (1995) Evidence for a connection between the mismatch repair system and the G2 cell cycle checkpoint. Cancer Res 55(17):3721–3725PubMed Hawn MT, Umar A, Carethers JM et al (1995) Evidence for a connection between the mismatch repair system and the G2 cell cycle checkpoint. Cancer Res 55(17):3721–3725PubMed
54.
Zurück zum Zitat Carethers JM, Hawn MT, Chauhan DP et al (1996) Competency in mismatch repair prohibits clonal expansion of cancer cells treated with N-methyl-N’-nitro-N-nitrosoguanidine. J Clin Invest 98(1):199–206PubMedCrossRef Carethers JM, Hawn MT, Chauhan DP et al (1996) Competency in mismatch repair prohibits clonal expansion of cancer cells treated with N-methyl-N’-nitro-N-nitrosoguanidine. J Clin Invest 98(1):199–206PubMedCrossRef
55.
Zurück zum Zitat Carethers JM, Chauhan DP, Fink D et al (1999) Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology 117(1):123–131PubMedCrossRef Carethers JM, Chauhan DP, Fink D et al (1999) Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology 117(1):123–131PubMedCrossRef
56.
Zurück zum Zitat Aebi S, Kurdi-Haidar B, Gordon R et al (1996) Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 56(13):3087–3090PubMed Aebi S, Kurdi-Haidar B, Gordon R et al (1996) Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 56(13):3087–3090PubMed
57.
Zurück zum Zitat Fink D, Nebel S, Aebi S et al (1996) The role of DNA mismatch repair in platinum drug resistance. Cancer Res 56(21):4881–4886PubMed Fink D, Nebel S, Aebi S et al (1996) The role of DNA mismatch repair in platinum drug resistance. Cancer Res 56(21):4881–4886PubMed
58.
Zurück zum Zitat Arnold CN, Goel A, Boland CR (2003) Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines. Int J Cancer 106(1):66–73PubMedCrossRef Arnold CN, Goel A, Boland CR (2003) Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines. Int J Cancer 106(1):66–73PubMedCrossRef
59.
Zurück zum Zitat Elsaleh H, Joseph D, Grieu F, Zeps N, Spry N, Iacopetta B (2000) Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet 355(9217):1745–1750PubMedCrossRef Elsaleh H, Joseph D, Grieu F, Zeps N, Spry N, Iacopetta B (2000) Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet 355(9217):1745–1750PubMedCrossRef
60.
Zurück zum Zitat Boland CR, Goel A (2010) Microsatellite instability in colorectal cancer. Gastroenterology 138(6):2073–2087PubMedCrossRef Boland CR, Goel A (2010) Microsatellite instability in colorectal cancer. Gastroenterology 138(6):2073–2087PubMedCrossRef
61.
Zurück zum Zitat Ribic CM, Sargent DJ, Moore MJ et al (2003) Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349(3):247–257PubMedCrossRef Ribic CM, Sargent DJ, Moore MJ et al (2003) Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349(3):247–257PubMedCrossRef
62.
Zurück zum Zitat Galon J, Costes A, Sanchez-Cabo F et al (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313(5795):1960–1964PubMedCrossRef Galon J, Costes A, Sanchez-Cabo F et al (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313(5795):1960–1964PubMedCrossRef
63.
Zurück zum Zitat Fridman WH, Pages F, Sautes-Fridman C, Galon J (2012) The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 12(4):298–306PubMedCrossRef Fridman WH, Pages F, Sautes-Fridman C, Galon J (2012) The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 12(4):298–306PubMedCrossRef
64.
Zurück zum Zitat Burn J, Bishop DT, Mecklin JP et al (2008) Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N Engl J Med 359(24):2567–2578PubMedCrossRef Burn J, Bishop DT, Mecklin JP et al (2008) Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N Engl J Med 359(24):2567–2578PubMedCrossRef
65.
Zurück zum Zitat Burn J, Gerdes AM, Macrae F et al (2011) Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 378(9809):2081–2087PubMedCrossRef Burn J, Gerdes AM, Macrae F et al (2011) Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 378(9809):2081–2087PubMedCrossRef
Metadaten
Titel
The History of Lynch Syndrome
verfasst von
C. Richard Boland
Henry T. Lynch
Publikationsdatum
01.06.2013
Verlag
Springer Netherlands
Erschienen in
Familial Cancer / Ausgabe 2/2013
Print ISSN: 1389-9600
Elektronische ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-013-9637-8

Weitere Artikel der Ausgabe 2/2013

Familial Cancer 2/2013 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.